ASHVATTHA THERAPEUTICS
Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.
ASHVATTHA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.avttx.com
Total Employee:
11+
Status:
Active
Contact:
650-868-5853
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Google Maps Global Site Tag Google Universal Analytics
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Modi Ventures
Modi Ventures investment in Series B - Ashvattha Therapeutics
Plum Alley
Plum Alley investment in Series B - Ashvattha Therapeutics
Tribe Capital
Tribe Capital investment in Series B - Ashvattha Therapeutics
Huadong Medicine
Huadong Medicine investment in Series B - Ashvattha Therapeutics
Natural Capital Investment Fund
Natural Capital Investment Fund investment in Series B - Ashvattha Therapeutics
Helios Capital
Helios Capital investment in Convertible Note - Ashvattha Therapeutics
Sakya Duvvuru
Sakya Duvvuru investment in Convertible Note - Ashvattha Therapeutics
Kingsley Advani
Kingsley Advani investment in Convertible Note - Ashvattha Therapeutics
Sand Hill Angels
Sand Hill Angels investment in Convertible Note - Ashvattha Therapeutics
Natural Capital
Natural Capital investment in Convertible Note - Ashvattha Therapeutics
Key Employee Changes
Official Site Inspections
http://www.avttx.com Semrush global rank: 7.86 M Semrush visits lastest month: 685
- Host name: ashvattha.tempurl.host
- IP address: 45.32.137.155
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Ashvattha Therapeutics"
About Us – Ashvattha Therapeutics - avttx.com
Co-founder, Board Observer, Co-Director, Center for Nanomedicine, Professor of Ophthalmology at Johns Hopkins UniversitySee details»
Technology – Ashvattha Therapeutics - avttx.com
Selective Uptake – only by activated inflammatory cells in diseased tissue; Systemic Delivery – oral or injectable; Crosses Tissue Barriers – blood/brain; blood/retinalSee details»
Ashvattha Therapeutics - Crunchbase Company Profile …
Avttx.com ; 18,880; Highlights. obfuscated. Total Funding Amount . Unlock for free . Contacts 22. Employee Profiles 4. Investors 17. Similar Companies 5. ... Which industries do these Sub-Organization operate in? Show . Orpheris …See details»
Ashvattha Therapeutics, Inc. | LinkedIn
Ashvattha Therapeutics, Inc. | 2,206 followers on LinkedIn. Harnessing the power of hydroxyl dendrimers to create a new class of disease cell-targeted precision medicine | Ashvattha Therapeutics ...See details»
Ashvattha Therapeutics - Craft
Ashvattha Therapeutics is a company that focuses on precision nanomedicines. It offers a potent anti-angiogenic nanomedicine (“dendranib”) D-4517.2, a positron emission tomography (PET) …See details»
Ashvattha Therapeutics - VentureRadar
Website: https://avttx.com. Develops novel hydroxyl dendrimer therapeutics for oncology, ophthalmology, and inflammatory diseases, aiming to revolutionize targeted treatment and …See details»
Ashvattha Therapeutics Announces Attendance at Upcoming …
Feb 18, 2021 For more information, visit: www.avttx.com. Contacts. Investors Matt Brewer Ashvattha Therapeutics [email protected] 303-717-9446 Media Kimberly Ha KKH Advisors …See details»
Ashvattha Therapeutics Announces Key Executive …
Mar 1, 2022 Investors Jeffrey L Cleland, PhD Ashvattha Therapeutics [email protected] 650-505-5048 Media Kimberly Ha KKH Advisors [email protected] 917-291-5744 Site Navigation. Home.See details»
D-4517.2 – Ashvattha Therapeutics - avttx.com
Over 10M eye injections per year = Heavy treatment burden on patients and doctors; Approved and prospective drugs require a retinal ophthalmologist, a caregiver to drive to/from visits, and an expensive treatmentSee details»
Ashvattha Therapeutics Announces First Patient Dosed via
Nov 1, 2023 Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For …See details»
Ashvattha Therapeutics Announces Appointment of Dr. Sakura …
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics …See details»
Ashvattha Therapeutics Announces $69 Million in Series B
Apr 27, 2022 – Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum Alley Investments and Tribe Capital –See details»
Ashvattha Therapeutics Announces Poster Presentation of
Aug 15, 2023 Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple …See details»
Pipeline – Ashvattha Therapeutics - avttx.com
D-4517.2 D-4517.2 is a potent anti-angiogenic nanomedicine (“dendranib”) that crosses the blood-retinal barrier and selectively targets activated microglia, macrophages and retinal pigment …See details»
Ashvattha Therapeutics Presents Transformative Anti …
Apr 26, 2021 For more information, visit: www.avttx.com. Contacts. Investors Matt Brewer Ashvattha Therapeutics [email protected] 303-717-9446 Media Kimberly Ha KKH Advisors …See details»
Ashvattha Therapeutics Announces Two Oral Presentations at the …
Sep 29, 2021 Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and …See details»
Ashvattha Therapeutics to Present at Upcoming Investor …
Feb 2, 2023 For more information, visit: www.avttx.com. Media Contact Sky Striar LifeSci Communications 617-797-6672 [email protected]. Categories Press Release. …See details»
Ashvattha Therapeutics Subsidiary Orpheris Announces FDA …
May 28, 2020 The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled evaluation of the safety, tolerability, and efficacy of OP-101 in patients with severe COVID-19 …See details»
Ashvattha Therapeutics Announces Positive Interim Data from …
Jun 15, 2021 Investors Matt Brewer Ashvattha Therapeutics [email protected] 303-717-9446 Media Julie Normart Real Chemistry [email protected] 559-974-3245 ContactsSee details»